BioSpace News Archive

CalciMedica Inc. (“CalciMedica” or the “Company”), the CRAC channel company, today announced the publication of preclinical data validating calcium release-activated calcium (CRAC) channels, P2Y2 receptors, and P2X receptors as potential drug targets for diseases of the airways in the peer-reviewed Journal of Immunology.

Seven Bridges, the industry-leading bioinformatics ecosystem provider, and Scripps Research have been awarded a $7.5M contract to develop a federated data ecosystem for the National Institute of Allergy and Infectious Diseases (NIAID) under a project titled the NIAID Data Ecosystem (NDE).

DiaCarta Inc. announced the publication of a study entitled “Target Enrichment Enhances the Sensitivity of Sanger Sequencing for BRAF V600 Mutation Detection” in bioRxiv.

Gaumard Scientific Co., today commented on the recent findings published in Obstetrics and Gynecology documenting a reduction of malpractice claims rates by obstetrician-gynecologists who participated in medical simulation training.

Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021 at 2:00 p.m. Eastern Time.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Annual Global Investment Conference, which runs from September 13 – 15, 2021.

Genus, a leading global animal genetics company, announces its preliminary results for the year ended 30 June 2021.

Soin Therapeutics, a pharmaceutical company based in Dayton, OH, was granted orphan drug status from the FDA for low dose naltrexone to treat complex regional pain syndrome.

Gan & Lee Pharmaceuticals Co., Ltd., is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Association for the Study of Diabetes Meeting.

ONK Therapeutics Ltd, an innovative NK cell therapy company, announced that the US Patent and Trademark Office has granted its licensed patent that covers CISH knockout in NK cells, irrespective of the source of the NK cells, including, for example, human cord blood-derived and human induced pluripotent stem cell -derived cells.